We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Sony DADC BioSciences and TSMC Receive AACC Award

By LabMedica International staff writers
Posted on 29 Jul 2014
Print article
The American Association for Clinical Chemistry (AACC) presented Sony DADC BioSciences and Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC; Hsinchu, Taiwan) with the AACC Industry Division Award.

The winning abstract, “Versatile Electrical Platform for Accelerated Development and Commercialization of In-Vitro Diagnostic Assays,” describes a process to integrate a novel silicon biosensor into a microfluidic chip, which has the potential to enable customers to design cost-effective, mass-fabricated Point-of-Care (POC) devices with better sensitivity and higher robustness than other available solutions.

The award is selected by a committee formed by the Chair of the AACC Industry Division, and given to research deemed to present a significant contribution to the in vitro diagnostic industry in management, regulatory affairs, or improved patient care, through a new or improved medical device.

The award-winning research combines Sony DADC BioSciences’ position in original equipment manufacturer (OEM) manufacturing of smart polymer-based consumables and TSMC’s deep expertise in silicon biosensor manufacturing. It aims to overcome a major hurdle for further development of point-of-care (POC) devices by improving material compatibility and positional alignment between silicon and plastics. Both partners have applied best-in-class silicon and plastic material-sciences to create a demonstrator for a novel hybrid design. The novelty of the silicon biosensor manufactured by TSMC is complemented by solid-state bonding of silicon to microstructured plastics developed by Sony DADC BioSciences.

Closing the gap between macro and micro interfaces allows simple and robust instrument interfaces, which serve the needs of POC environments. Both companies together will engage in discussions with diagnostic industry leaders as early adopters of the new manufacturing techniques to integrate biosensors.

Dr. Christoph Mauracher, senior vice president at Sony DADC BioSciences Sony DADC BioSciences notes, “Sony DADC BioSciences has enjoyed the cooperative development with TSMC to create a novel silicon-plastic fluidic interface which enables simple integration of microfluidic functionalities like filters, mixers, valves and pumps while ensuring a robust sample input and waste management.”

Related Links:

Sony DADC BioSciences
TSMC


Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
RNA Isolation Kits
RNeasy Plus Kits for RNA Isolation
New
Blood Gas Panel plus Electrolytes
i-STAT EG6+ Cartridge

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.